​

​

​

​

​

 

Derisk investments through our unmatched pipeline and market vision. See the whole oncology field, beyond fragmented pitch decks, to lead your strategic investments or company creation with confidence.​​

​​

Comprehensive Landscape Analysis

Expand the scope of your due diligence to the full cancer therapeutics universe

​​​

    Evaluate 2,500+ oncology companies and 5,900+ assets across 35 metrics for technical success 

    Assess biotech acquisition/licensing potential across each pharmaceutical company

    Proactively detect underrepresented targets or mechanisms that align with your thesis

​​​

Uncover companies with asymmetric upside and clear paths to liquidity events

​​​

Interrogate Platform Differentiation

Discern impactful science from futile hand-waving

​​

    Understand how 2,500+ companies each fit into the cancer therapeutics ecosystem

    Contextualize isolated company materials across the entire sector 

    Pinpoint proprietary approaches that'll drive meaningful commercial outcomes

​

Generate outsized returns by avoiding me-too science and overly crowded markets

​

Align Your Incentives with Pharma & Patients

Tap into the clinical benchmarks and patient populations that matter

​​

    Extract the safety/efficacy metrics needed to turn your portfolio into industry standouts

    Monitor the evolving patient landscape to detect expanding unmet need populations

    Aggregate insights for all stakeholders across the clinical and commercial landscapes​

​​

Leverage the right data and back companies that are positioned to win